https://nsc266046inhibitor.com..../a-brand-new-family-
Anemia is a common complication for patients with kidney illness. Roxadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI), which can be a newly approved oral medicine for anemia. We performed this study to build evidence regarding efficacy and protection of roxadustat in renal condition patients with otherwise without dialysis. We searched the databases of PubMed, Embase, Cochrane library and clinicaltrials.gov from the creation
Me gusta
Comentario
Compartir
